Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity

Summary

To investigate the efficacy and tolerability of the regimen of dolutegravir plus lamivudine in HIV infected adults who are virologically suppressed and with evidence of TDF toxicity.

Timeline

Start

2022-08

Primary completion

2025-08

Completion

2026-06

Publications

• Wang Z, Liu L, Chen J, Wang J, Shen Y, Qi T, Tang Y, Song W, Sun J, Xu S, Yang J, Chen Y, Shao Y, Zhang R. Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed HIV-1 Infected Adults with TDF-Related Renal or Bone Toxicity. Infect Dis Ther. 2026 Jul;15(7):1913-1924. doi: 10.1007/s40121-026-01363-y. Epub 2026 May 20.

Drugs

Indications